Daily Sepsis Research Analysis
Analyzed 36 papers and selected 3 impactful papers.
Summary
Three papers stood out today: a JCI prospective multi-omics study defines an IL-6/IFN-γ-driven pediatric sepsis endotype with baseline STAT1/3 hyperactivation, nominating the JAK/STAT axis as a therapeutic target; an EMBO Molecular Medicine translational study links TCA-cycle–centric metabolism to improved neonatal infection defense and proposes nutrition-based strategies; and a large multicenter registry shows red blood cell transfusion above restrictive thresholds in septic shock is associated with higher mortality, challenging lactate-justified liberal transfusion.
Research Themes
- Immune endotyping and JAK/STAT targeting in pediatric sepsis
- Metabolic reprogramming and nutrition to enhance neonatal host defense
- Transfusion thresholds and the limits of lactate-guided practice in septic shock
Selected Articles
1. Aberrant STAT signaling and T cell dysregulation define a targetable pediatric sepsis endotype.
Prospective multi-omics profiling of 88 critically ill children identified an IL-6/IFN-γ–driven hyperinflammatory endotype with T cell dysfunction and baseline STAT1/3 hyperactivation that failed to respond to TCR stimulation. These convergent data nominate the JAK/STAT pathway as a rational immunomodulatory target in pediatric sepsis.
Impact: Defines a mechanistically coherent, targetable immune endotype in pediatric sepsis using state-of-the-art multi-omics and functional assays.
Clinical Implications: Supports immune endotyping to stratify pediatric sepsis and provides a rationale to test JAK/STAT inhibitors or IL-6–targeted strategies in biomarker-enriched trials.
Key Findings
- Unsupervised cytokine clustering revealed three subgroups; the highest severity group was driven by IL-6 and IFN-γ hypercytokinemia.
- CD8+ T cells in the high-severity group showed baseline STAT1/STAT3 hyperactivation and failed to respond to αCD3/αCD28/αCD49d stimulation.
- Single-cell RNA-seq demonstrated suppression of a lymphoid protective gene program across CD8+ subsets with bystander activation and no dominant clonotypes.
- Data converge on the JAK/STAT axis as a targetable pathway in a defined pediatric sepsis endotype.
Methodological Strengths
- Prospective cohort integrating multi-omics (plasma proteomics, scRNA-seq) and phosphoflow cytometry
- Unsupervised clustering with convergent validation across modalities
Limitations
- Single-cohort sample size of 88 limits generalizability and statistical power for subgroup analyses
- Observational design without interventional validation of JAK/STAT targeting
Future Directions: Biomarker-driven interventional trials of JAK/STAT inhibitors or IL-6/IFN-γ modulation in the Group C endotype, with external validation cohorts.
BACKGROUND: Sepsis is a leading cause of morbidity and mortality in critically ill children, yet heterogeneous immune responses complicate the development of targeted therapies and the host immune factors driving sepsis pathobiology remain unclear. METHODS: We integrated deep immune phenotyping, plasma proteomics, single-cell transcriptomics, and phosphoflow cytometry in a prospective cohort of 88 critically ill children to elucidate the mechanisms underlying immune heterogeneity. RESULTS: Unsupervised clust
2. Harnessing the glycolysis-TCA cycle axis to boost host defense against neonatal infection.
A human birth cohort (n=700) linked higher plasma TCA metabolites to fewer infections and lower inflammation. In a piglet neonatal sepsis model, nutrition that shifts energy flux from glycolysis to TCA-driven oxidative phosphorylation (e.g., substituting glucose with galactose or glucogenic amino acids) improved pathogen clearance, preserved glucose homeostasis, and prevented lethal sepsis.
Impact: Establishes a translational link between systemic energy metabolism and neonatal infection defense with actionable nutrition-based strategies.
Clinical Implications: Suggests rethinking parenteral/enteral nutrition composition in high-risk neonates to support TCA-cycle flux; motivates early-phase trials testing galactose or glucogenic amino acid–enriched formulations.
Key Findings
- In a 700-child birth cohort, higher plasma TCA-cycle metabolites associated with reduced infection burden and systemic inflammation.
- In a piglet neonatal sepsis model, sustained hepatic TCA activity correlated with survival.
- Replacing glucose with galactose or glucogenic amino acids improved pathogen clearance, preserved glucose homeostasis, and prevented lethal sepsis.
- Mechanistically, nutrition promoted hepatic rewiring from glycolysis to TCA-based oxidative phosphorylation, mitigating inflammation and organ injury.
Methodological Strengths
- Triangulation across a human birth cohort and a controlled piglet sepsis model
- Mechanistic linkage between nutritional substrate choice and metabolic/immune outcomes
Limitations
- Human cohort associations are observational and may be confounded
- Preclinical piglet interventions require validation in human neonatal trials
Future Directions: Randomized neonatal nutrition trials testing TCA-supportive formulations with infection and metabolic endpoints; multi-omics biomarker development for patient selection.
Preterm infants are highly susceptible to infections that can lead to sepsis, yet therapies beyond antibiotics are limited. Nutrition and host energy metabolism are known as immune modulators, but how they interact to mediate newborn host infection defense remains poorly understood. Here, we identify tricarboxylic acid (TCA) cycle metabolites as key modulators of early life infection outcomes. First, in a birth cohort of 700 children, elevated plasma TCA metabolite levels were associated with redu
3. Dietary tryptophan supplementation prevents sepsis by enhancing macrophage bacterial defense through GPR37 activation.
Dietary tryptophan reshaped gut microbial metabolism to increase the GPR37 ligand indole-3-pyruvate, which directly bound GPR37 on macrophages to activate RAC1/CDC42 and Arp2/3, enhancing phagocytosis and protecting mice from sepsis. Gpr37 knockout and macrophage transfer experiments established receptor dependence, and IPyA boosted phagocytosis in human macrophages.
Impact: Reveals a previously unrecognized Trp–microbial metabolite–GPR37 axis that mechanistically augments macrophage antibacterial function and mitigates sepsis.
Clinical Implications: Points to GPR37 and its ligand pathway as immunometabolic targets; motivates prophylactic or adjunctive strategies (dietary Trp or IPyA analogs) pending safety/efficacy in humans.
Key Findings
- Dietary tryptophan increased microbial indole-3-pyruvate, which directly bound GPR37 on macrophages.
- GPR37 activation triggered RAC1/CDC42 and Arp2/3 upregulation, enhancing bacterial phagocytosis and improving survival in sepsis models.
- Gpr37 knockout or macrophage-specific knockdown abrogated protection; IPyA enhanced phagocytosis in human macrophages.
Methodological Strengths
- Multi-tier validation including knockout mice, siRNA in macrophages, adoptive transfer, and ligand–receptor binding assays
- Human relevance shown by IPyA-induced phagocytosis in patient-derived macrophages
Limitations
- Preclinical mouse-centric efficacy; no in vivo human outcome data
- Potential microbiome variability may affect translatability of dietary interventions
Future Directions: Phase I/II trials assessing safety and immunologic endpoints of Trp/IPyA-based strategies; medicinal chemistry to develop potent, selective GPR37 agonists.
BACKGROUND: Sepsis, a critical and life-threatening condition, is one of the most common causes of death among inpatients. Emerging evidence suggests that active metabolites derived from gut microbe-associated metabolism of dietary essential amino acid L-tryptophan (Trp) help the host in combating infectious diseases. This study aims to investigate the mechanisms through which these active metabolites regulate sepsis progression. METHODS: The effects of dietary Trp and indole-3-pyruvate (IPyA)